SCHEMBL4914736

SCHEMBL4914736

Cc1cc(Nc2c(N[C@H](C)c3cccc(O)c3)c(=O)c2=O)cc(C)c1O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPKAPK2 P49137 17/20 0.70
AURKB Q96GD4 4/20 0.49
ROCK1 Q13464 3/20 0.49
PDGFRA P16234 3/20 0.49
MAPK1 P28482 3/20 0.49
CSNK1G1 Q9HCP0 3/20 0.49
CYP2C9 P11712 2/20 0.49
RPS6KA1 Q15418 2/20 0.49
DCLK1 O15075 1/20 0.49
ROCK2 O75116 1/20 0.49
CHEK2 O96017 1/20 0.49
GSK3A P49840 1/20 0.49
GSK3B P49841 1/20 0.49
IRAK1 P51617 1/20 0.49
PRKX P51817 1/20 0.49
NEK4 P51957 1/20 0.49
PLK1 P53350 1/20 0.49
CSNK1G2 P78368 1/20 0.49
CDC42BPA Q5VT25 1/20 0.49
BRSK1 Q8TDC3 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1228998 0.88 MAPKAPK2 (0.67) MAPKAPK2AURKBROCK1PDGFRAMAPK1
SCHEMBL4914345 0.88 MAPKAPK2 (0.67) MAPKAPK2AURKBROCK1PDGFRAMAPK1
SCHEMBL4919825 0.87 MAPKAPK2 (0.54) MAPKAPK2AURKBROCK1PDGFRAMAPK1
SCHEMBL4366319 0.82 MAPKAPK2 (1.00) MAPKAPK2AURKBROCK1PDGFRAMAPK1
SCHEMBL1229214 0.81 MAPKAPK2 (0.59) MAPKAPK2AURKBROCK1PDGFRAMAPK1
SCHEMBL1229134 0.81 MAPKAPK2 (0.59) MAPKAPK2AURKBROCK1PDGFRAMAPK1
SCHEMBL4911215 0.80 MAPKAPK2 (0.67) MAPKAPK2AURKBROCK1PDGFRAMAPK1
SCHEMBL4906889 0.79 MAPKAPK2 (0.65) MAPKAPK2AURKBROCK1PDGFRAMAPK1
SCHEMBL4915655 0.78 MAPKAPK2 (0.64) MAPKAPK2AURKBROCK1PDGFRAMAPK1
SCHEMBL4914122 0.77 MAPKAPK2 (0.63) MAPKAPK2AURKBROCK1PDGFRAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080262096-A1 Squaric Acid Derivatives MERCK PATENT GMBH (DE) 2008-10-23 US claimed
EP-1838662-A1 SQUARIC ACID DERIVATIVES Merck Patent GmbH (DE) 2007-10-03 EP claimed
WO-2006072354-A1 SQUARIC ACID DERIVATIVES MERCK PATENT GMBH (DE) 2006-07-13 WO claimed
US-20080262096-A1 Squaric Acid Derivatives MERCK PATENT GMBH (DE) 2008-10-23 US disclosed
EP-1838662-A1 SQUARIC ACID DERIVATIVES Merck Patent GmbH (DE) 2007-10-03 EP disclosed
WO-2006072354-A1 SQUARIC ACID DERIVATIVES MERCK PATENT GMBH (DE) 2006-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262096-A1 Squaric Acid Derivatives GLS, SGK1, PFKL MAPKAPK2 1309/4885AURKB 1018/4885ROCK1 593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.